Empros schreef op 13 maart 2018 11:20:
Hi Chappie, goede morgen,
Ik denk niet dat ik je iets spectaculairs kan bieden hoor....alleen geduld!
Mijn redenering is als volgt: Canopy sinds 2014 kent een verdubbeling in revenue met een huidige waardering van ca.6.3 billion Dlrs of >90 x revenue....
De huidige koerswaarde van CAD 32.49 verdubbelen zie ik niet zo gebeuren dit jaar, zelfs met de recreatieve legalisering midden dit jaar...aldus nu reeds dik winst genomen met het doel van uitbreiding in Emblem.
Ik blijf dik LONG met Aurora, Aphria,CBW , Emblem.
De fundamenten van Emblem zijn sterk (beneden meer detail) met de huidige focus op "medicinale produkten" inclusief CBD oils.
Hogerop 12/03-09.23h "Emblem Corp CEO Nick Dean Talks about their Game Plan for 2018".
In het algemeen zijn de sentimenten bullish en de consensus CAD 2.75.
nl.investing.com/equities/emblem-corp...Als IPO is Emblem niet als een "petty stock" uit de startblokken geschoten met 100den % (in tegendeel).Ik voorzie eerder een verdubbeling van dit aandeel einde 2018/begin 2019....of een overname door 1 van de 2 Unicorns.
QCTrader samenvatting:
"Ticker: $EMC.v
Shares outstanding: 90m
Market cap: 160m$
Cashed up position: roughly 90m$ in the bank.
Warrants: 30m shares
Options: 6m shares
Raises:
Prior to IPO raises:23.7m$ @ 1.15$
Raise after IPO: 15m$ Special warrants convertible @ 3.63$ half warrants 4.75$
Recent raises: 26m$ @ 1.75$ half warrants @ 2.15, 50m$ @ 2.05$ half warrants @2.30$
Assets:
Facility size: 23 500 sqrft + 4 800 sqrft offices
Land size: 3 acres + 1.2 acre + 80 acres(short walk distance)
Expansion: 30 000 sqrft GMP extraction/lab (expected completion june/july)
Expansion 2: starts second Q of 2018, 120k sqrft greenhouse + 50k facility expansion planned.
Licenses: production+sales + oils
GrowWise Health Limited
Clinic business, Emblem owns 50% with option to acquire remaining 50%
GrowWise operated multiple clinics in partnership with the White Cedar Medical Cannabis Doctors clinic chain.
GrowWise has 14 locations and has registered 4000 patients with licensed producers (doesnt mention Active Patients versus Registered)
Canntab Therapeutics Limited
EMC and Canntab has an agreement for r&d for the purpose of an oral sustained release pills or capules targed for early 2019 (under Emblem Brand)
Ongoing R&D
Vape pens and the related concentrate technology, pills, gel caps, sub-lingual applications and measured dose nasal sprays
Expansion land advantages:
Natural gas infrastructure available to these lands will allow Emblem to "go off the grid", generating electricity and cogenerating heat and CO2 and allowing the Company to become a low-cost producer.
Management:
Recent change in CEO, Nick Dean is the new captain, has over 12 years of consumer marketing and leadership experience. Previously worked in pharmaceuticals and healthcare brands, including LCBO.
Emblem, had a rough year, when first came to market it was extremely hyped due to the John H. Stewart connection and his past with Oxycotin and Pharma industry. So EMC came down and down, never really executed on expansions, their revenues went down, their share price took a dive, bleeded the hell out of it, EMC was also the only tax-loss candidate of the marijuana sector for 2017, so that didnt help the December run.
Why invest in Emblem?
Well we, investors, are always looking at a share price opportunity (valuation) versus peers.
And most often those gap in valuation versus comparables are created by mistakes by management. Recently management has changed, 75m$ was raised, they are slowly executing behind the scene and not flashing the pump news releases.
The biggest reason to invest in Emblem at this moment would be their cash position versus market cap, how often can you invest in a marijuana company with half their valuation in cash in the bank? not very often.
The second biggest reason to invest in Emblem is the recent canadian sector went up roughly 250% from low levels, EMC is at its lowest despite their biggest cash position.
I could go on and compare multiple marijuana company that had a cash position close to half their market cap and 100% of those company received a more than 50% share price appreciation in the coming weeks/months. (HVST,MARI,EMH,CMM,)
market cap is roughly 170m$ they have roughly 90m$ in the bank, add roughly 30m$ for their land, facility, extra land, GrowWise clinic, ongoing agreements. not much downside at this level versus 99% of Canadian marijuana companies"